Brokers Set Expectations for Kura Oncology FY2026 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Analysts at Brookline Capital Markets lifted their FY2026 earnings per share (EPS) estimates for shares of Kura Oncology in a report issued on Tuesday, November 10th. Brookline Capital Markets analyst L. Cann now anticipates that the company will earn ($3.35) per share for the year, up from their previous estimate of ($3.48). The consensus estimate for Kura Oncology’s current full-year earnings is ($3.25) per share. Brookline Capital Markets also issued estimates for Kura Oncology’s Q4 2026 earnings at ($0.97) EPS, FY2027 earnings at ($2.47) EPS and FY2028 earnings at ($2.30) EPS.

A number of other analysts also recently weighed in on KURA. Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a report on Thursday. Deutsche Bank set a $24.00 target price on Kura Oncology in a research note on Wednesday, October 14th. JPMorgan Chase & Co. started coverage on Kura Oncology in a report on Thursday, October 1st. They issued an “overweight” rating and a $30.00 target price on the stock. Morgan Stanley set a $24.00 price target on Kura Oncology in a research note on Monday, August 24th. Finally, UBS Group set a $24.00 price target on Kura Oncology in a report on Thursday. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.88.

Kura Oncology Price Performance

KURA stock opened at $7.43 on Friday. The company has a quick ratio of 4.71, a current ratio of 3.60 and a debt-to-equity ratio of 0.07. Kura Oncology has a 12 month low of $6.75 and a 12 month high of $13.90. The firm has a market cap of $682.67 million, a P/E ratio of -2.25 and a beta of 0.56. The company’s 50-day moving average price is $10.28 and its two-hundred day moving average price is $9.77.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Tuesday, November 10th. The company reported ($0.78) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.04. Kura Oncology had a negative return on equity of 336.24% and a negative net margin of 369.26%. The business had revenue of $22.84 million during the quarter, compared to the consensus estimate of $24.94 million.

Institutional Trading of Kura Oncology

A number of hedge funds have recently made changes to their positions in the company. BlackRock Inc. bought a new stake in shares of Kura Oncology in the second quarter worth $115,286,000. Bank of America Corp DE bought a new position in Kura Oncology during the 2nd quarter worth $12,735,000. Dimensional Fund Advisors LP lifted its holdings in Kura Oncology by 32.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock worth $11,591,000 after buying an additional 348,127 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Kura Oncology during the 2nd quarter worth about $10,927,000. Finally, Aberdeen Group plc bought a new stake in shares of Kura Oncology in the 3rd quarter valued at about $8,443,000.

Insiders Place Their Bets

In other Kura Oncology news, insider Brian Powl sold 17,020 shares of the firm’s stock in a transaction that occurred on Monday, September 28th. The shares were sold at an average price of $10.53, for a total value of $179,220.60. Following the sale, the insider owned 152,249 shares in the company, valued at $1,603,181.97. This trade represents a 10.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Teresa Bair sold 31,487 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $12.63, for a total value of $397,680.81. Following the completion of the transaction, the insider owned 195,444 shares of the company’s stock, valued at $2,468,457.72. The trade was a 13.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 153,881 shares of company stock worth $1,708,183 over the last 90 days. Insiders own 7.60% of the company’s stock.

Trending Headlines about Kura Oncology

Here are a few of the latest headlines about KURA:

• Positive Sentiment: Kura said it expects to receive $25 million in funding, which could add financial flexibility. Funding announcement
• Positive Sentiment: Third-quarter results highlighted 53% growth in KOMZIFTI revenue and progress on pipeline plans for 2027, potential commercial and development catalysts. Q3 results and pipeline plans
• Neutral Sentiment: HC Wainwright raised its 2026–2029 EPS forecasts, now projecting smaller losses in each year; Brookline also modestly improved its 2026–2028 estimates. These revisions are supportive, but remain projections rather than evidence that Kura has reached profitability.

Kura Oncology Company Profile

Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.